Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Cannabinoids vs. C. diff.
July 2018
SHARING OPTIONS:

LOS ANGELES—Vitality Biopharma Inc. has reported new findings detailing the antimicrobial activity of cannabinoids and their potential for treating C. difficile-associated diarrhea and colitis. Vitality has demonstrated that cannabinoids including THC can serve as effective antibiotics for C. diff., vancomycin-resistant Enterococci and other pathogens. The company has submitted a patent application for related intellectual property and plans to evaluate VBX-100—a proprietary gastrointestinal-targeted THC compound—as a treatment for C. diff.-associated diarrhea and colitis.
 
Dr. Brandon Zipp, Vitality’s Director of R&D, commented that “Our recent studies show that cannabinoids may be useful for both addressing the inflammatory state of the colon, as well as confronting the microbial dysbiosis at the root of the problem. This represents a new possible mechanism for cannabinoids, yet is very much in-line with the current scientific understanding that cannabinoids can play a prominent role in promoting intestinal homeostasis and long-term healing.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.